Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020

C. Adlhoch, C. Delgado-Sanz, A. Carnahan, A. Larrauri, O. Popovici, N. Bossuyt, I. Thomas, J. Kynčl, P. Slezak, M. Brytting, R. Guiomar, M. Redlberger-Fritz, J. Maistre Melillo, T. Melillo, AB. van Gageldonk-Lafeber, SD. Marbus, J. O'Donnell, L....

. 2023 ; 28 (4) : . [pub] -

Language English Country Sweden

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc23004696

Grant support
001 World Health Organization - International

BackgroundTimely treatment with neuraminidase inhibitors (NAI) can reduce severe outcomes in influenza patients.AimWe assessed the impact of antiviral treatment on in-hospital deaths of laboratory-confirmed influenza patients in 11 European Union countries from 2010/11 to 2019/20.MethodsCase-based surveillance data from hospitalised patients with known age, sex, outcome, ward, vaccination status, timing of antiviral treatment, and hospitalisation were obtained. A mixed effect logistic regression model using country as random intercept was applied to estimate the adjusted odds ratio (aOR) for in-hospital death in patients treated with NAIs vs not treated.ResultsOf 19,937 patients, 31% received NAIs within 48 hours of hospital admission. Older age (60-79 years aOR 3.0, 95% CI: 2.4-3.8; 80 years 8.3 (6.6-10.5)) and intensive care unit admission (3.8, 95% CI: 3.4-4.2) increased risk of dying, while early hospital admission after symptom onset decreased risk (aOR 0.91, 95% CI: 0.90-0.93). NAI treatment initiation within 48 hours and up to 7 days reduced risk of dying (0-48 hours aOR 0.51, 95% CI: 0.45-0.59; 3-4 days 0.59 (0.51-0.67); 5-7 days 0.64 (0.56-0.74)), in particular in patients 40 years and older (e.g. treatment within 48 hours: 40-59 years aOR 0.43, 95% CI: 0.28-0.66; 60-79 years 0.50 (0.39-0.63); ≥80 years 0.51 (0.42-0.63)).ConclusionNAI treatment given within 48 hours and possibly up to 7 days after symptom onset reduced risk of in-hospital death. NAI treatment should be considered in older patients to prevent severe outcomes.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004696
003      
CZ-PrNML
005      
20230425171651.0
007      
ta
008      
230418s2023 sw f 000 0|eng||
009      
AR
024    7_
$a 10.2807/1560-7917.ES.2023.28.4.2200340 $2 doi
035    __
$a (PubMed)36700868
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sw
100    1_
$a Adlhoch, Cornelia $u European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
245    10
$a Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020 / $c C. Adlhoch, C. Delgado-Sanz, A. Carnahan, A. Larrauri, O. Popovici, N. Bossuyt, I. Thomas, J. Kynčl, P. Slezak, M. Brytting, R. Guiomar, M. Redlberger-Fritz, J. Maistre Melillo, T. Melillo, AB. van Gageldonk-Lafeber, SD. Marbus, J. O'Donnell, L. Domegan, J. Gomes Dias, SJ. Olsen
520    9_
$a BackgroundTimely treatment with neuraminidase inhibitors (NAI) can reduce severe outcomes in influenza patients.AimWe assessed the impact of antiviral treatment on in-hospital deaths of laboratory-confirmed influenza patients in 11 European Union countries from 2010/11 to 2019/20.MethodsCase-based surveillance data from hospitalised patients with known age, sex, outcome, ward, vaccination status, timing of antiviral treatment, and hospitalisation were obtained. A mixed effect logistic regression model using country as random intercept was applied to estimate the adjusted odds ratio (aOR) for in-hospital death in patients treated with NAIs vs not treated.ResultsOf 19,937 patients, 31% received NAIs within 48 hours of hospital admission. Older age (60-79 years aOR 3.0, 95% CI: 2.4-3.8; 80 years 8.3 (6.6-10.5)) and intensive care unit admission (3.8, 95% CI: 3.4-4.2) increased risk of dying, while early hospital admission after symptom onset decreased risk (aOR 0.91, 95% CI: 0.90-0.93). NAI treatment initiation within 48 hours and up to 7 days reduced risk of dying (0-48 hours aOR 0.51, 95% CI: 0.45-0.59; 3-4 days 0.59 (0.51-0.67); 5-7 days 0.64 (0.56-0.74)), in particular in patients 40 years and older (e.g. treatment within 48 hours: 40-59 years aOR 0.43, 95% CI: 0.28-0.66; 60-79 years 0.50 (0.39-0.63); ≥80 years 0.51 (0.42-0.63)).ConclusionNAI treatment given within 48 hours and possibly up to 7 days after symptom onset reduced risk of in-hospital death. NAI treatment should be considered in older patients to prevent severe outcomes.
650    _2
$a lidé $7 D006801
650    _2
$a senioři $7 D000368
650    12
$a oseltamivir $x terapeutické užití $7 D053139
650    12
$a chřipka lidská $x farmakoterapie $x epidemiologie $7 D007251
650    _2
$a neuraminidasa $7 D009439
650    _2
$a mortalita v nemocnicích $7 D017052
650    _2
$a antivirové látky $x terapeutické užití $7 D000998
650    _2
$a inhibitory enzymů $x terapeutické užití $7 D004791
650    _2
$a guanidiny $x terapeutické užití $7 D006146
650    _2
$a zanamivir $x terapeutické užití $7 D053243
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Delgado-Sanz, Concepción $u National Centre of Epidemiology, CIBERESP, Carlos III Health Institute, Madrid, Spain
700    1_
$a Carnahan, AnnaSara $u Public Health Agency of Sweden, Stockholm, Sweden
700    1_
$a Larrauri, Amparo $u National Centre of Epidemiology, CIBERESP, Carlos III Health Institute, Madrid, Spain
700    1_
$a Popovici, Odette $u National Institute of Public Health Romania-National Centre for Communicable Diseases Surveillance and Control, Bucharest, Romania
700    1_
$a Bossuyt, Nathalie $u Sciensano, Brussels, Belgium
700    1_
$a Thomas, Isabelle $u Sciensano, Brussels, Belgium
700    1_
$a Kynčl, Jan $u Department of Infectious Diseases Epidemiology, National Institute of Public Health, Prague, Czechia
700    1_
$a Slezak, Pavel $u Department of Infectious Diseases Epidemiology, National Institute of Public Health, Prague, Czechia
700    1_
$a Brytting, Mia $u Public Health Agency of Sweden, Stockholm, Sweden
700    1_
$a Guiomar, Raquel $u National Influenza Reference Laboratory, National Institute of Health Dr. Ricardo Jorge, Lisbon, Portugal
700    1_
$a Redlberger-Fritz, Monika $u Center for Virology, Medical University Vienna, Vienna, Austria
700    1_
$a Maistre Melillo, Jackie $u Infectious Disease prevention and Control unit, Malta
700    1_
$a Melillo, Tanya $u Infectious Disease prevention and Control unit, Malta
700    1_
$a van Gageldonk-Lafeber, Arianne B $u National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
700    1_
$a Marbus, Sierk D $u National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
700    1_
$a O'Donnell, Joan $u Health Service Executive-Health Protection Surveillance Centre, Dublin, Ireland
700    1_
$a Domegan, Lisa $u Health Service Executive-Health Protection Surveillance Centre, Dublin, Ireland
700    1_
$a Gomes Dias, Joana $u European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
700    1_
$a Olsen, Sonja J $u WHO Regional Office for Europe, Copenhagen, Denmark
773    0_
$w MED00174364 $t Euro surveillance : bulletin Europeen sur les maladies transmissibles European communicable disease bulletin $x 1560-7917 $g Roč. 28, č. 4 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36700868 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425171647 $b ABA008
999    __
$a ok $b bmc $g 1925029 $s 1190905
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 28 $c 4 $e - $i 1560-7917 $m Euro surveillance $n Euro Surveill $x MED00174364
GRA    __
$a 001 $p World Health Organization $2 International
LZP    __
$a Pubmed-20230418
Back

Find record

Citation metrics

Archiving options